GlassScriptPhysician profile
Annette Williams
NPI 1689083784
$2,308.27
in general payments reported to CMS, 2019-2025
33 companies · $712 in 2025
The $712 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $278 · 2022: $303 · 2023: $445 · 2024: $570 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $378.32 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $212.22 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Glaxosmithkline, LLC. | $195.78 | 2021-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $138.43 | 2022-2024 | Spravato |
| Lilly USA, LLC | $114.40 | 2021-2024 | Jardiance, Zepbound, Emgality |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.62 | 2021-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $108.27 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Ironshore Pharmaceuticals INC. | $88.89 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $76.87 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $75.73 | 2022-2025 | Auvelity |
| Exact Sciences Corporation | $74.71 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $67.22 | 2022 | |
| Lundbeck LLC | $63.96 | 2021 | |
| Vanda Pharmaceuticals INC. | $54.51 | 2025 | Fanapt |
| Sage Therapeutics, LLC | $53.70 | 2024-2025 | Zurzuvae |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $52.86 | 2025 | Wegovy, Rybelsus, Ozempic |
| Dexcom, INC. | $52.66 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $52.25 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.95 | 2021-2023 | Trintellix |
| Phathom Pharmaceuticals, INC. | $32.36 | 2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $29.24 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $27.15 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $24.57 | 2024 | |
| Abbott Laboratories | $22.60 | 2025 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $22.49 | 2021 | |
| Jazz Pharmaceuticals INC. | $17.50 | 2021 | |
| Almatica Pharma LLC | $16.94 | 2024 | Loreev Xr |
| Astellas Pharma US INC | $16.94 | 2025 | Veozah |
| Sumitomo Pharma America, INC. | $16.84 | 2024 | Gemtesa |
| Tonix Medicines, INC. | $15.92 | 2025 | Tonmya |
| Csl Behring | $15.43 | 2024 | Haegarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.69 | 2023 | Jardiance |
| Amgen INC. | $11.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.